ACE-031 vs Enclomiphene
Emerging vs Well Studied
synergistic Mechanism-based · 46% Enclomiphene supports hormonal recovery from suppression caused by ACE-031. Standard protocol — begin PCT after the suppressive compound has cleared based on its half-life.
Molecular Data
ACE-031 Enclomiphene
Weight — 405.96 Da
Half-life 12-15 days ~10 hours
Type Soluble activin receptor type IIB-Fc fusion protein Trans-isomer of clomifene (selective estrogen receptor modulator)
Key Benefits
ACE-031
01 Significant lean mass increases (up to 1.7% in 29 days) observed in Phase 1 trials
02 Simultaneous reduction in fat mass alongside muscle gains
03 Long half-life (12-15 days) allows infrequent dosing
04 Broad TGF-beta ligand neutralization for robust anti-catabolic effects
05 Dose-dependent increases in thigh muscle volume confirmed by MRI
Enclomiphene
01 Raises endogenous testosterone by stimulating the HPTA axis
02 Preserves fertility and spermatogenesis (unlike exogenous testosterone)
03 No estrogenic agonist activity (unlike racemic clomifene/Clomid)
04 Oral dosing with no injections required
05 Does not suppress the HPTA or cause testicular atrophy
06 Effective for post-cycle therapy and secondary hypogonadism
07 Well-tolerated with a favorable side effect profile
Dosing Protocols
ACE-031
0.5-3 mg/kg IV every 2 weeks (clinical research doses only) / Every 2 weeks
Phase 1 Research Protocol (Healthy Volunteers) 0.1-3 mg/kg Single IV dose
Phase 2 Research Protocol (DMD) 0.5-2.5 mg/kg Every 2 weeks
Enclomiphene
12.5-25mg oral daily / Once daily (morning preferred)
Side Effects
ACE-031
Nosebleeds (epistaxis) - most frequently reported adverse event
Gum bleeding
Telangiectasia (dilated small blood vessels visible on skin)
Skin erythema (redness)
Minor injection site reactions
Enclomiphene
Headache
Nausea or mild gastrointestinal discomfort
Hot flashes or flushing
Mood changes (irritability or emotional sensitivity)
Fatigue during initial adjustment
Contraindications
NEVER approved for human use - clinical development discontinued
History of bleeding disorders or vascular malformations
Concurrent anticoagulant or antiplatelet therapy
Known hypersensitivity to Fc fusion proteins
Pregnancy or breastfeeding
Known hypersensitivity to clomifene or enclomiphene
Pre-existing liver disease or significantly elevated liver enzymes
Active or history of thromboembolic disorders
Pregnancy or women who may become pregnant (teratogenic risk)
Primary hypogonadism (testicular failure -- enclomiphene requires functional testes)
Pituitary tumors or undiagnosed pituitary pathology
Research Evidence
ACE-031 Enclomiphene
Status Emerging Well Studied
References 4 studies 5 studies
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.